Cited 43 times in
Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜련 | - |
dc.contributor.author | 조병철 | - |
dc.date.accessioned | 2018-07-20T07:47:21Z | - |
dc.date.available | 2018-07-20T07:47:21Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/160523 | - |
dc.description.abstract | OBJECTIVES: To characterize the expression of PD-L1, PD-1, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and T-cell immunoglobulin and mucin-domain containing-3 (TIM3) in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Samples from 90 patients with newly diagnosed advanced stage NSCLC harboring EGFR mutations and treated with first line EGFR tyrosine kinase inhibitors (TKI) within 3 months of diagnosis were stained for CTLA-4, PD-L1, PD-1, TIM-3 and CD3 expression by immunohistochemistry. RESULTS: PD-L1 was present in at least 1% of immune and tumor cells in 44% and 59% of samples, respectively. In multivariate analysis, increased CD3 immune shaped cell (ISC) counts (HR 2.805, p=0.034) and high PD-L1 tumor H-score (HR 3.805, p=0.022) was associated with a shorter progression free survival and high CTLA-4 ISC counts was associated with borderline overall survival significance (HR 1.054, p=0.061). CONCLUSION: Tumor PD-L1 expression was significantly associated with a shorter PFS whereas immune cell CTLA-4 may be prognostic for OS. Our findings support the ongoing development of CTLA-4 and PD1/PD-L1 inhibitors in this important molecularly defined subset of lung adenocarcinoma. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier Scientific Publishers | - |
dc.relation.isPartOf | LUNG CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | B7-H1 Antigen/metabolism | - |
dc.subject.MESH | Biomarkers, Tumor/metabolism | - |
dc.subject.MESH | CD3 Complex/metabolism | - |
dc.subject.MESH | CTLA-4 Antigen/metabolism | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/genetics | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hepatitis A Virus Cellular Receptor 2/metabolism | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms/genetics | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Programmed Cell Death 1 Receptor/metabolism | - |
dc.subject.MESH | Protein Kinase Inhibitors/administration & dosage | - |
dc.subject.MESH | Protein Kinase Inhibitors/therapeutic use | - |
dc.subject.MESH | Receptor, Epidermal Growth Factor/genetics | - |
dc.subject.MESH | Survival Analysis | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Ross A. Soo | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Bernadette Reyna Asuncion | - |
dc.contributor.googleauthor | Zul Fazreen | - |
dc.contributor.googleauthor | Mohamed Feroz Mohd Omar | - |
dc.contributor.googleauthor | Maria Cynthia Herrera | - |
dc.contributor.googleauthor | Joey Sze Yun Lim | - |
dc.contributor.googleauthor | Grace Sia | - |
dc.contributor.googleauthor | Richie Soong | - |
dc.contributor.googleauthor | Byoung-Chul Cho | - |
dc.identifier.doi | 10.1016/j.lungcan.2017.01.008 | - |
dc.contributor.localId | A01166 | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J02174 | - |
dc.identifier.eissn | 1872-8332 | - |
dc.identifier.pmid | 28236980 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0169500217300090 | - |
dc.subject.keyword | Cytotoxic T-lymphocyte antigen-4 | - |
dc.subject.keyword | Epidermal growth factor receptor mutations | - |
dc.subject.keyword | Non-small cell lung cancer | - |
dc.subject.keyword | Programmed death ligand-1 | - |
dc.subject.keyword | T-cell immunoglobulin | - |
dc.subject.keyword | mucin-domain containing-3 | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.citation.volume | 105 | - |
dc.citation.startPage | 17 | - |
dc.citation.endPage | 22 | - |
dc.identifier.bibliographicCitation | LUNG CANCER, Vol.105 : 17-22, 2017 | - |
dc.identifier.rimsid | 44257 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.